Search / Trial NCT06236516

One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Jan 23, 2024

Trial Information

Current as of October 09, 2024

Recruiting

Keywords

Sbrt Lung Cancer Oligometastatic Cancer Image Guided Radiotherapy Adaptive Radiotherapy

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * One of the following diagnoses:
  • * Histologically or radiographically diagnosed stage I-IIA (AJCC, 8th ed.) non-small cell lung cancer .
  • * Clinical AJCC stage I defined as stage 1A1 (T1a1N0M0, T1a tumor less than or equal to 1 cm), stage 1A2 (T1bN0M0, T1b tumor between 1 and 2 cm), and stage 1A3 (T1cN0M0, T1c tumor between 2 and 3 cm).
  • * Clinical AJCC stage IB defined as T2aN0M0, T2a tumor between 3 and 4 cm.
  • * Clinical AJCC stage IIA defined as T2bN0M0, T2b tumor between 4 and 5 cm.
  • * Oligometastatic lung tumor secondary to a primary cancer of any type/histology. Oligometastatic patients may include patients with:
  • * 1-5 sites of metastatic disease with at least one lung lesion intended to be treated with SBRT
  • * More than 5 sites of metastatic disease with oligo-progressive disease in the lung intended to be treated with SBRT.
  • * Lesions must be small and peripheral.
  • * Small is defined as max tumor dimension of 5 cm or less.
  • * Peripheral is defined as greater than 2 cm from the proximal bronchial tree/mediastinum.
  • * Tumors and anatomy amenable to one-fraction lung SBRT confirmed by meeting of one-fraction lung SBRT target and constraint metrics on a diagnostic-scan based preplan.
  • * Patients who do not meet this criterion will be screen fails and triaged to the standard lung SBRT workflow and treated off trial.
  • * Lesions must have a maximum superior to inferior motion of 1 cm on 4D-CT imaging.
  • * Patients who do not meet this criteria will be screen fails and triaged to the standard lung SBRT workflow and treated off trial.
  • * At least 18 years of age.
  • * Able to understand and willing to sign an IRB approved written informed consent.
  • Exclusion Criteria:
  • * Past history of radiotherapy within the projected treatment field of any of the disease sites to be treated by ONE STOP SBRT.
  • * Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 14 days of ONE STOP SBRT.

About Washington University School Of Medicine

Washington University School of Medicine is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research, education, and patient care. With a strong emphasis on translating scientific discoveries into practical applications, the institution conducts a diverse array of clinical trials aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. Its collaborative environment fosters partnerships between researchers, clinicians, and community stakeholders, ensuring that the trials not only contribute to scientific knowledge but also address the pressing health needs of diverse populations.

Locations

Saint Louis, Missouri, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0